SIGLEC1 and neoplasm: CD169(+) macrophages as lymph node-resident antigen presenting cells (APCs) dominate early activation of tumor antigen-specific CD8(+) T cells and have been demonstrated to play a crucial role in tumor immune activation [45,46].